4Harris GK, Qian Y, Leonard SS, et al. Luteolin and chrysin differentially inhibit cyclooxygenase-2 expres- sion and scavenge reactive oxygen species but similarly inhibit prostaglandin-E2 formation in RAW 264. 7 cells [J]. J Nutr, 2006,136(6) :1517-1521.
5Hwang JT, Park OJ, Lee YK,et al. Anti-tumor effect of luteolin is accompanied by AMP-activated protein ki- nase and nuclear factor-B modulation in HepG2 hepa- tocarcinoma cells[J]. Int J Mol Med, 2011,28 (1) : 25-31.
7Masters TN, Fokin AA, Sehaper J, et al. Changes in the preserved heart that limit the length of preservation[J]. J Heart Lung Transplant, 2002, 21(5):590-599.
8Demmy TL, Turpin TA, Wagner-Mann CC. Laborato- ry confirmation of clinical heart allograft preservation variability[J]. Ann Thorae Surg, 2001, 71(4) : 1312- 1319.
9Stringham JC, Love RB, Welter D, et al. Impact of U- niversity of Wisconsin solution on clinical heart trans- plantation. A comparison with Stanford solution for ex- tended preservation[J]. Circulation, 1998,98(19 Sup- pl) : 157-162.
10Mankad P, Slavik Z, Yacoub M. Endothelial dysfunc- tion caused by University of Wisconsin preservation so- lution in the rat heart. The importance of temperature [J]. J Thorac Cardiovasc Surg, 1992, 104 (6) : 1618- 1624.
